Search

Royalty Pharma PLC (Class A)

Slēgts

SektorsVeselības aprūpe

58.55 -1.1

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

57.86

Max

59.54

Galvenie mērījumi

By Trading Economics

Ienākumi

-589M

-295M

Pārdošana

44M

674M

P/E

Sektora vidējais

30.511

57.002

EPS

1.32

Dividenžu ienesīgums

1.6

Peļņas marža

-43.713

Darbinieki

100

EBITDA

-387M

176M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+10.89% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

1.60%

2.22%

Nākamie ieņēmumi

2026. g. 4. nov.

Nākamais dividenžu datums

2026. g. 10. sept.

Nākamais Ex dividenžu datums

2026. g. 14. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

577M

33B

Iepriekšējā atvēršanas cena

59.65

Iepriekšējā slēgšanas cena

58.55

Royalty Pharma PLC (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. aug. 20:02 UTC

Social Media

Royalty Pharma PLC shares are lower amid a $100 million royalty agreement with Zealand Pharma for rusfertide rights, reflecting unusual trading activity.

2026. g. 12. aug. 20:01 UTC

Royalty Pharma PLC shares are higher today, supported by a broader market trend of gains since Tuesday. The stock is seeing unusually high trading volume.

2026. g. 11. aug. 19:56 UTC

Royalty Pharma PLC shares are trading higher, reaching a session high earlier today. No specific news was identified to explain the price movement.

2026. g. 10. aug. 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting notable strength and unusual activity since Monday's close, with no specific news identified.

2026. g. 7. aug. 23:41 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting notable gains since Friday's close amid a shift toward a dovish monetary policy outlook.

2026. g. 6. aug. 23:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, moving above Thursday's close, despite remaining below the 20-day moving average.

2026. g. 5. aug. 19:31 UTC

News

Royalty Pharma PLC raised its full-year guidance for Portfolio Receipts to $3.4 billion to $3.5 billion, contributing to a higher trading session.

2026. g. 4. aug. 19:26 UTC

Royalty Pharma PLC shares are higher today, rebounding after earlier pulling back from a session high. The stock has fluctuated within a routine range.

2026. g. 3. aug. 23:46 UTC

Royalty Pharma PLC shares are near unchanged in after-market trading, reflecting minimal movement since Monday's close and remaining below the 20-day moving average.

2026. g. 1. aug. 00:03 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline over the past four sessions. No specific news was identified to explain the move.

2026. g. 31. jūl. 23:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting broader market trends despite some gains in mega-cap stocks. The stock remains below its 20-day moving average.

2026. g. 30. jūl. 22:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting strong demand and trading above its 20-day moving average. No specific news was identified.

2026. g. 29. jūl. 19:27 UTC

Royalty Pharma PLC shares are lower today, reflecting a pullback since Tuesday's close amid rising oil prices and inflation concerns.

2026. g. 28. jūl. 23:46 UTC

Royalty Pharma PLC shares are lower in after-market trading, reflecting broader market declines amid concerns over technology sector dynamics.

2026. g. 27. jūl. 16:46 UTC

Royalty Pharma PLC shares are advancing during Monday's session. Broader market gains are supported by a notable decline in oil prices amid easing geopolitical tensions.

2026. g. 24. jūl. 22:21 UTC

In after-market trading, Royalty Pharma PLC is trading higher, nearing the upper end of its one-month range after recovering from an early low.

2026. g. 22. jūl. 19:11 UTC

News
Event

Royalty Pharma acquires a royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront payment. Shares are trading roughly flat.

2026. g. 21. jūl. 17:51 UTC

Royalty Pharma PLC shares are higher today, tracking broader market gains, with unusually high trading volume noted. No specific news was identified for the movement.

2026. g. 20. jūl. 19:21 UTC

Royalty Pharma PLC shares are lower as the Pharmaceuticals sector faces downward pressure, with unusually high trading volume noted today.

Salīdzinājums

Cenas izmaiņa

Royalty Pharma PLC (Class A) Prognoze

Cenas mērķis

By TipRanks

10.89% augšup

Prognoze 12 mēnešiem

Vidējais 65.67 USD  10.89%

Augstākais 70 USD

Zemākais 62 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Royalty Pharma PLC (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

7

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat